CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/12/2018 |
| Start Date: | January 31, 2014 |
| End Date: | November 2019 |
A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
The purpose of this study is to see if the investigator can help the immune system to work
against myeloma.
This study will see if a vaccine made with altered dendritic cells will make T cells work
against tumor cells. The stem cells collected for the transplant will also be used to grow
dendritic cells in the lab. The dendritic cells will carry the antigens. These cells then
will be injected under the skin. The investigators will do lab studies before and after the
vaccination to find out if the vaccine is working.
against myeloma.
This study will see if a vaccine made with altered dendritic cells will make T cells work
against tumor cells. The stem cells collected for the transplant will also be used to grow
dendritic cells in the lab. The dendritic cells will carry the antigens. These cells then
will be injected under the skin. The investigators will do lab studies before and after the
vaccination to find out if the vaccine is working.
Inclusion Criteria:
- Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.
- Completion of induction therapy with Very Good Partial Response (VGPR), or better, by
International Myeloma Working Group (IMWG) criteria.
- Deemed eligible for ASCT by standard institutional criteria.
- Age ≥18 years.
- Documentation of CT7, MAGE-A3, or WT1 expression in the bone marrow and/or bone marrow
aspirate.
Exclusion Criteria:
- Prior autologous or allogeneic SCT.
- Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.
- Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.
- History of autoimmune disease (e.g., rheumatoid arthritis, SLE), other than vitiligo,
diabetes, or treated thyroiditis, which are allowed.
- History of severe allergic reactions to vaccines or unknown allergens.
- Participation in any other clinical trial involving another investigational agent
within 4 weeks prior to first immunization.
- Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part
of treatment.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: David Chung, MD, PhD
Phone: 212-639-6617
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
